• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Reply to Letter to Editor: "HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?".致编辑信件的回复：“雌激素受体（ER）阳性乳腺癌患者的HER2阳性：它真的具有预后价值吗？”
Breast. 2021 Feb;55:137. doi: 10.1016/j.breast.2020.11.011. Epub 2020 Nov 21.
2
Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.雌激素或孕激素受体阴性表达在腔面B型HER2阴性乳腺癌患者中的预后价值
World J Surg Oncol. 2016 Sep 13;14(1):244. doi: 10.1186/s12957-016-0999-x.
3
High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.高Ki-67表达和低孕激素受体表达可独立导致雌激素受体阳性且人表皮生长因子受体2阴性的绝经后乳腺癌患者预后较差。
Clin Breast Cancer. 2015 Jun;15(3):204-11. doi: 10.1016/j.clbc.2014.12.007. Epub 2014 Dec 24.
4
Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.PgR表达作为通过Ki67标记指数分类的中度风险ER阳性/HER2阴性乳腺癌患者预后因素的作用。
BMC Cancer. 2017 May 22;17(1):354. doi: 10.1186/s12885-017-3331-4.
5
Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.绝经后激素受体阳性、HER2 阴性乳腺癌患者接受芳香化酶抑制剂新辅助内分泌治疗后，孕激素受体与术前内分泌预后指数（PEPI）联合作为预后因素的影响。
PLoS One. 2018 Aug 6;13(8):e0201846. doi: 10.1371/journal.pone.0201846. eCollection 2018.
6
Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.雌激素受体、孕激素受体及人表皮生长因子受体2在乳腺癌细针穿刺抽吸细胞块及配对组织学标本中的表达：一项大型回顾性研究。
Cancer Cytopathol. 2016 Nov;124(11):828-835. doi: 10.1002/cncy.21745. Epub 2016 Jun 17.
7
HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?雌激素受体（ER）阳性乳腺癌患者中的HER2阳性：它真的具有预后价值吗？
Breast. 2021 Feb;55:136. doi: 10.1016/j.breast.2020.11.017. Epub 2020 Nov 30.
8
Reply letter to: Role of endocrine therapy in weak estrogen/progesterone receptor expression in HER2 negative breast cancer.
Eur J Surg Oncol. 2018 Apr;44(4):540. doi: 10.1016/j.ejso.2018.01.081. Epub 2018 Jan 31.
9
Does androgen receptor have a prognostic role in patients with estrogen/progesterone-negative and c-erbB-2-positive breast cancer?雄激素受体在雌激素/孕激素阴性且c-erbB-2阳性的乳腺癌患者中是否具有预后作用？
Am Surg. 2012 Sep;78(9):992-9.
10
HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.激素受体阳性的绝经前原发性乳腺癌中的HER2状态可提供预后信息，但不能预测他莫昔芬的治疗效果。
Breast Cancer Res Treat. 2008 May;109(2):351-7. doi: 10.1007/s10549-007-9660-2. Epub 2007 Jul 18.

本文引用的文献

1
HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab.在接受化疗和曲妥珠单抗治疗的高危雌激素受体阳性早期乳腺癌患者中，HER2 阳性与不良预后无关。
Breast. 2020 Dec;54:235-241. doi: 10.1016/j.breast.2020.10.002. Epub 2020 Oct 15.
2
Towards personalized treatment for early stage HER2-positive breast cancer.针对早期 HER2 阳性乳腺癌的个体化治疗。
Nat Rev Clin Oncol. 2020 Apr;17(4):233-250. doi: 10.1038/s41571-019-0299-9. Epub 2019 Dec 13.
3
Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.人表皮生长因子受体 2（HER2）阳性和激素受体阳性乳腺癌：分子相互作用和临床意义的新见解。
Ann Oncol. 2013 Nov;24(11):2715-24. doi: 10.1093/annonc/mdt287. Epub 2013 Aug 1.
4
Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010.根据激素受体和 Her2 免疫组化确定的不同肿瘤亚型，乳腺癌患者的生存和临床病理特征。一项跨越 1998 年至 2010 年的单机构调查。
Breast. 2012 Jun;21(3):366-73. doi: 10.1016/j.breast.2012.03.004. Epub 2012 Apr 7.
5
HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.激素受体阳性的绝经前原发性乳腺癌中的HER2状态可提供预后信息，但不能预测他莫昔芬的治疗效果。
Breast Cancer Res Treat. 2008 May;109(2):351-7. doi: 10.1007/s10549-007-9660-2. Epub 2007 Jul 18.

Reply to Letter to Editor: "HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?".

作者信息

Li Shuai, Chen Xiaosong

机构信息

Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.

Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.

出版信息

Breast. 2021 Feb;55:137. doi: 10.1016/j.breast.2020.11.011. Epub 2020 Nov 21.

DOI:10.1016/j.breast.2020.11.011
PMID:33262007
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7878442/
Abstract
摘要